Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Journal of Colorectal Disease
Erschienen in: International Journal of Colorectal Disease 9/2009

01.09.2009 | Original Article

ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery

verfasst von: Glauco Baiocchi, Ademar Lopes, Renata A. Coudry, Benedito M. Rossi, Fernando A. Soares, Samuel Aguiar, Gustavo C. Guimarães, Fabio O. Ferreira, Wilson T. Nakagawa

Erschienen in: International Journal of Colorectal Disease | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Investigate ErbB family expression in colorectal cancer patients with higher risk of recurrence after surgical treatment.

Methods

We studied 109 individuals with high risk stage II and stage III patients submitted to radical surgery. ErbB expression was assessed by tissue microarray technique.

Results

The immunohistochemical expression was considered positive for EGFR, ErbB2, ErbB3, ErbB4 membrane, and ErbB4 cytoplasmic in respectively 57.8%, 8.3%, 69.7%, 11%, and 19.3% of patients. ErbB3 negative expression was associated with lymphovascular invasion. EGFR, ErbB2, and cytoplasmic ErbB4 expression was not associated with prognosis. Membranous positive ErbB4 expression was an independent prognostic factor for recurrence. ErbB3 negative expression was an independent prognostic factor for recurrence and survival in the multivariate analysis.

Conclusions

The immunohistochemical expression of ErbB3 and ErbB4 may identify a subgroup with stage II and III colorectal cancer at higher risk of recurrence.
Literatur
1.
2.
Nelson H, Petrelli N, Carlin A et al (2001) National Cancer Institute Expert Panel. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93(8):583–96PubMedCrossRef
3.
Gelb AB, Schrock TR (1997) Prognostic factors in colorectal carcinomas. Surg Oncol Clin N Am 6(3):463–94PubMed
4.
Ratto C, Sofo L, Ippoliti M et al (1998) Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum 41(8):1033–49PubMedCrossRef
5.
Compton C, Fenoglio-Preiser CM, Pettigrew N et al (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88(7):1739–57PubMedCrossRef
6.
Greene FL, Page DL, Fleming ID et al (2002) AJCC Cancer Staging Manual—6th ed. Springer-Verlag, New YorkCrossRef
7.
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264(11):1444–50.
8.
Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–19PubMedCrossRef
9.
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–37PubMedCrossRef
10.
Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341–54PubMedCrossRef
11.
Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102(1):37–46PubMedCrossRef
12.
Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–16PubMedCrossRef
13.
Finnegan TJ, Carey LA (2007) Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 3(1):55–63PubMedCrossRef
14.
Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469–87PubMedCrossRef
15.
Sergina NV, Moasser MM (2007) The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13(12):527–34 Epub 2007PubMedCrossRef
16.
Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–82PubMedCrossRef
17.
Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16(6):413–28PubMedCrossRef
18.
Jeong EG, Soung YH, Lee JW et al (2006) ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer 119(12):2986–7PubMedCrossRef
19.
Karamouzis MV, Badra FA, Papavassiliou AG (2007) Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 39(5):851–6PubMedCrossRef
20.
Sartor CI, Zhou H, Kozlowska E et al (2001) Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21(13):4265–75PubMedCrossRef
21.
Compton C, Fenoglio-Preiser CM, Pettigrew N et al (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88(7):1739–57PubMedCrossRef
22.
Compton C, Fielding LP, Burgart LJ et al (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):979–94PubMed
23.
Kountourakis P, Pavlakis K, Psyrri A et al (2006) Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6:46PubMedCrossRef
24.
Jacobs TW, Gown AM, Yaziji H et al (1999) Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17(7):1983–7PubMed
25.
Yasui W, Sumiyoshi H, Hata J et al (1988) Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 48(1):137–41PubMed
26.
Spano JP, Lagorce C, Atlan D et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16(1):102–8PubMedCrossRef
27.
McKay JA, Murray LJ, Curran S et al (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38(17):2258–64PubMedCrossRef
28.
Scartozzi M, Bearzi I, Berardi R et al (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22(23):4772–8PubMedCrossRef
29.
Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92(5):1331–46PubMedCrossRef
30.
Steele RJ, Kelly P, Ellul B et al (1990) Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 77(12):1352–4PubMedCrossRef
31.
Galizia G, Lieto E, Ferraraccio F et al (2006) Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 13(6):823–35PubMedCrossRef
32.
Nathanson DR, Culliford AT 4th, Shia J et al (2003) HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105(6):796–802PubMedCrossRef
33.
Schuell B, Gruenberger T, Scheithauer W et al (2006) HER 2/neu protein expression in colorectal cancer. BMC Cancer 6:123PubMedCrossRef
34.
Ochs AM, Wong L, Kakani V et al (2004) Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer 4(4):262–7PubMedCrossRef
35.
McKay JA, Loane JF, Ross VG et al (2002) c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 86(4):568–73PubMedCrossRef
36.
Essapen S, Thomas H, Green M et al (2004) The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 24(2):241–8PubMed
37.
Osako T, Miyahara M, Uchino S et al (1998) Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 55(6):548–55PubMedCrossRef
38.
Kluftinger AM, Robinson BW, Quenville NF et al (1992) Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1(1):97–105PubMedCrossRef
39.
Cunningham MP, Essapen S, Thomas H et al (2006) Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 28(2):329–35PubMed
40.
Maurer CA, Friess H, Kretschmann B et al (1998) Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29(8):771–7PubMedCrossRef
41.
Kapitanović S, Radosević S, Slade N et al (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 126(4):205–11PubMedCrossRef
42.
Lee JC, Wang ST, Chow NH et al (2002) Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38(8):1065–71PubMedCrossRef
43.
Kountourakis P, Pavlakis K, Psyrri A et al (2006) Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6:46PubMedCrossRef
44.
Koumakpayi IH, Diallo JS, Le Page C et al (2006) Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 12(9):2730–7PubMedCrossRef
45.
Feroz K, Williams E, Riese DJ 2nd (2002) ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cell Signal 14(9):793–8PubMedCrossRef
46.
Zlobec I, Terracciano L, Jass JR et al (2007) Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 451(4):763–9PubMedCrossRef
47.
Goethals L, Perneel C, Debucquoy A et al (2006) A new approach to the validation of tissue microarrays. J Pathol 208(5):607–14PubMedCrossRef
48.
Torhorst J, Bucher C, Kononen J et al (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159(6):2249–56PubMed
49.
Moch H, Schraml P, Bubendorf L et al (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154(4):981–6PubMed
Metadaten
Titel
ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery
verfasst von
Glauco Baiocchi
Ademar Lopes
Renata A. Coudry
Benedito M. Rossi
Fernando A. Soares
Samuel Aguiar
Gustavo C. Guimarães
Fabio O. Ferreira
Wilson T. Nakagawa
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 9/2009
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-009-0702-6

Weitere Artikel der Ausgabe 9/2009

International Journal of Colorectal Disease 9/2009 Zur Ausgabe

Original Article

Comparison of two sodium phosphate tablet-based regimens and a polyethylene glycol regimen for colon cleansing prior to colonoscopy: a randomized prospective pilot study

Original Article

Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer

Original Article

Lymphatic vessel invasion detected by monoclonal antibody D2-40 as a predictor of lymph node metastasis in T1 colorectal cancer

Original Article

Ligasure™ versus diathermy hemorrhoidectomy under spinal anesthesia or pudendal block with ropivacaine: a randomized prospective clinical study with 1-year follow-up

Letter to the Editor

The value of sacral nerve stimulation in the treatment of faecal incontinence after pelvic radiotherapy

Original Article

Retrograde colonic irrigation for faecal incontinence after low anterior resection

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.